Ricardo Machado, MD
Cardiovascular Disease · Hialeah, FLNPI 1598736969
Payments from drug & device makers
Across 365 payments — averaging $245.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$41K
- Amarin Pharma, Inc.$24K
- Novartis$10K
- Abbott$4K
- Biotronik Inc.$3K
- Boston Scientific$1K
- plus $6K from 33 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$69,63878%
- Travel & lodging$2,2302%
- Food & beverage$17,14919%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 48 | $40,631 |
| Amarin Pharma, Inc. | 35 | $24,302 |
| Novartis | 21 | $9,628 |
| Abbott | 67 | $4,444 |
| Biotronik Inc. | 25 | $2,973 |
| Boston Scientific | 15 | $1,061 |
| Amgen | 8 | $822 |
| AstraZeneca | 8 | $730 |
| Pfizer | 25 | $573 |
| Medtronic(2 entities) | 5 | $573 |
| Boehringer Ingelheim | 20 | $393 |
| Actelion Pharmaceuticals US, Inc. | 4 | $375 |
| Philips North America LLC | 9 | $368 |
| Atricure, Inc. | 3 | $327 |
| E.r. Squibb & Sons, L.L.C. | 15 | $300 |
| Edwards Lifesciences | 2 | $259 |
| Angiodynamics, Inc. | 2 | $255 |
| Heartflow, Inc. | 3 | $245 |
| ZOLL Circulation Inc | 1 | $148 |
| Merck | 8 | $135 |
| Lexicon Pharmaceuticals, Inc. | 4 | $112 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Bayer | 4 | $97 |
| Scpharmaceuticals Inc. | 3 | $80 |
| Irhythm Technologies, Inc. | 2 | $73 |
| Gilead | 4 | $71 |
| Kestra Medical Technology Services, Inc. | 3 | $59 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| United Therapeutics Corporation | 1 | $32 |
| GE HealthCare | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Osprey Medical Inc | 1 | $23 |
| Surmodics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Cvrx, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$39,733
- Vascepa$24,002
- ENTRESTO$9,448
- AVEIR$962
- MitraClip$617
- Repatha$610
- BioMonitor$519
- FARXIGA$499
- Mitra Clip system$396
- Edora$391
- Acticor$391
- Solia$391
- Rivacor$391
- MitraClip System$390
- Acticor 7 VR-T DX$373
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$323
- UPTRAVI$315
- OPSUMIT$315
- JOT DX$279
- Watchman$262
How this compares
$89,464 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 526 | $541,799 |
| XareltoRivaroxaban | 274 | $320,436 |
| EntrestoSacubitril/Valsartan | 210 | $243,559 |
| FarxigaDapagliflozin Propanediol | 147 | $134,641 |
| BrilintaTicagrelor | 99 | $80,874 |
| Repatha SureclickEvolocumab | 59 | $59,742 |
| MultaqDronedarone Hcl | 30 | $36,254 |
| VascepaIcosapent Ethyl | 63 | $32,429 |
| EdarbiAzilsartan Medoxomil | 43 | $13,935 |
| Ranolazine ErRanolazine | 87 | $8,109 |
| Metoprolol Succinate | 991 | $7,744 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 16 | $5,760 |
| Rosuvastatin Calcium | 454 | $4,671 |
| Nebivolol Hcl | 49 | $4,191 |
| Losartan Potassium | 557 | $3,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $573 | $541,799526 claims |
| Johnson & JohnsonXarelto | $40,631 | $320,436274 claims |
| NovartisEntresto | $9,628 | $243,559210 claims |
| AstraZenecaFarxiga, Brilinta | $730 | $215,515246 claims |
| Sanofi-aventis U.S. LLCMultaq | $110 | $36,25430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hialeah
- Alexis GutierrezHialeah$8M
- Raul AlonsoHialeah$2.1M
- Jose EscalanteHialeah$817K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.